

**Supply of Medicine****PATIENT GROUP DIRECTION (PGD) FOR****CHLORPHENAMINE MALEATE 4MG TABLETS AND 2MG IN 5ML SYRUP**

**YOU MUST BE AUTHORISED BY NAME, UNDER THE CURRENT VERSION OF THIS PGD BEFORE YOU ATTEMPT TO WORK ACCORDING TO IT**

<b>Clinical Condition</b>	
<b>Indication</b>	Symptomatic relief an allergic reaction resulting from a minor injury eg a sting or insect bite, in the absence of pyrexia. <b>NB: This PGD no longer covers use for hayfever or any other minor illness not related to a minor injury.</b>
<b>Inclusion criteria</b>	Patients 1 year old and over presenting at MIU with symptoms of a minor allergic reaction as above, and history which supports diagnosis. This is a sedating antihistamine. Do not supply unless there is a clear advantage e.g. to help sleep
<b>Exclusion criteria</b> If any of the following apply the PGD CANNOT be used and the patient must be referred to a prescriber	Children under the age of 1 year Allergy to chlorphenamine or other antihistamines Patients who have taken monoamine oxidase inhibitors (moclobemide, phenelzine, tranylcypromine, isocarboxacid) within the last 14 days. Patients with hayfever or an allergic reaction not related to a minor injury – refer to community pharmacy or prescriber Patient who has taken a sedating antihistamine in the previous four hours or a non sedating antihistamine in the preceding 12 hours or patients who have already taken an antihistamine without obtaining relief. Hepatic impairment. Pregnancy / breastfeeding Patient with epilepsy Individuals who have recently had alcohol, opioid analgesics, hypnotics or anxiolytics – may increase sedation. Individuals with cardiovascular disease, prostatic hypertrophy, urinary retention, glaucoma, gastric obstruction.
<b>Cautions - Seek further advice from doctor before proceeding and document advice</b>	May cause drowsiness, dizziness blurred vision and psychomotor impairment which may be more apparent in children or the elderly. Syrup contains sugar so caution with diabetic patients
<b>Further information</b>	Consider non-sedating antihistamine eg cetirizine unless drowsiness is desirable. Cetirizine is not covered by this PGD.
<b>Action if patient declines or is excluded</b>	Use alternative antihistamine if appropriate Refer to community pharmacy, GP or A & E as appropriate

**Supply of Medicine****PATIENT GROUP DIRECTION (PGD) FOR****CHLORPHENAMINE MALEATE 4MG TABLETS AND 2MG IN 5ML SYRUP**




<b>Drug Details</b>													
<b>Name, form &amp; strength of medicine</b>	Chlorphenamine maleate tablets 4mg (from 6 years old) Chlorphenamine maleate oral solution /syrup 2mg/5ml												
<b>Legal status</b>	P												
<b>Route/Method</b>	Oral												
<b>Dosage / frequency</b>	<table><thead><tr><th>Age</th><th>Dose</th></tr></thead><tbody><tr><td>1 year</td><td>1mg (2.5ml) twice a day</td></tr><tr><td>2 – 5 years</td><td>1mg (2.5ml) 4 to 6 hourly maximum 6mg</td></tr><tr><td>6 – 12 years</td><td>2mg (5ml) 4 to 6 hourly maximum 12mg</td></tr><tr><td>Adults</td><td>4mg tablet 4 to 6 hourly maximum 24mg</td></tr><tr><td>Elderly</td><td>4mg tablet 4 to 6 hourly maximum 12mg</td></tr></tbody></table>	Age	Dose	1 year	1mg (2.5ml) twice a day	2 – 5 years	1mg (2.5ml) 4 to 6 hourly maximum 6mg	6 – 12 years	2mg (5ml) 4 to 6 hourly maximum 12mg	Adults	4mg tablet 4 to 6 hourly maximum 24mg	Elderly	4mg tablet 4 to 6 hourly maximum 12mg
Age	Dose												
1 year	1mg (2.5ml) twice a day												
2 – 5 years	1mg (2.5ml) 4 to 6 hourly maximum 6mg												
6 – 12 years	2mg (5ml) 4 to 6 hourly maximum 12mg												
Adults	4mg tablet 4 to 6 hourly maximum 24mg												
Elderly	4mg tablet 4 to 6 hourly maximum 12mg												
<b>Duration of treatment</b>	See below												
<b>Quantity to supply</b>	One dose and /or supply 28 tablets or 150ml oral solution												
<b>Side effects</b>	Give patient information leaflet. Side effects include drowsiness, dizziness, headache, dry mouth, tinnitus, and blurred vision. Psychomotor impairment and urinary retention. Palpitations and dyspepsia												
<b>Advice to patient/carer</b>	If causes drowsiness, dizziness, blurred vision and psychomotor impairment do not drive or use machinery												

**Supply of Medicine**

**PATIENT GROUP DIRECTION (PGD) FOR**

**CHLORPHENAMINE MALEATE 4MG TABLETS AND 2MG IN 5ML SYRUP**

<b>Staff Characteristics</b>	
<b>Professional qualifications</b>	Nurses on the NMC Register
<b>Specialist competencies or qualifications</b>	Is trained to manage minor allergies in a MIU setting Has undertaken appropriate training for working under PGDs for the supply and administration of medicines Has undertaken training in the management of anaphylaxis
<b>Continuing education &amp; training</b>	It is the responsibility of the individual to keep up-to-date with clinical developments as part of their continued professional development.
<b>Referral Arrangements and Audit Trail</b>	
<b>Records/audit trail</b>	Patient's name, address, date of birth, Contact details of GP (if registered), Diagnosis, Dose and form administered or supplied, Advice given to patient (Including side effects/self care), Signature/name of staff who administered or supplied the medication. Details of any adverse drug reaction and actions taken including documentation in the patient's medical record Record the use of the PGD on departmental log sheet.
<b>References/Resources and comments</b>	Summary of Product Characteristics British National Formulary

<b>Clinical Authorisation</b>	
<b>Lead Doctor</b>	Dr John Devapriam, Medical Director  Signature:  Date: 5/12/18
<b>Lead Pharmacist</b>	Dr Alex Johnson, Prescribing Support Pharmacist  Signature:  Date: 12.12.18
<b>Organisational Authorisation</b>	
<b>On behalf of Worcestershire Health and Care NHS Trust</b>	Michelle Clarke, Director of Nursing & Quality  Signature:  Date: 6/12/18.
<b>Patient Group Direction Peer Reviewed by</b>	
<b>MIU Senior Nurses</b>	

